The Dubai Health Annual Report is now available. Click here to read our story. x
All in for Discovery
Our integrated academic health system is a rich ecosystem of resources, research facilities, advanced technology and specialized equipment. Our healthcare experts collaborate seamlessly with specialists in research and innovation to craft new treatment protocols and tailored therapies. This synergetic environment fosters a culture of curiosity and determination to push the limits of medical understanding. By embracing an academic methodology grounded in evidence, we ensure the integration of the latest breakthroughs into patient care, prioritizing safety and efficacy.
Where integration creates impact
Our integrated academic health system is a rich ecosystem of resources, boasting research facilities, cutting-edge technology, and specialized equipment. These assets empower our scientists and scholars to engage in impactful research. We champion interdisciplinary collaboration, encouraging experts from disparate fields to unite, sparking innovative research endeavors that draw strength from a multitude of perspectives.
Discovery in Numbers
Latest News & Events
Scientists at the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the learning and discovery arm of Dubai Health, have published the first Arab Pangenome Reference, marking a major milestone in both regional and global genomic research. The study, released in Nature Communications, a leading scientific journal, provides a crucial foundation for advancing precision medicine and personalised healthcare for Arab populations, while also supporting the UAE’s National Genome Strategy, a 10-year initiative launched in 2023 by the Emirates Genome Council to advance personalised, preventive, and precision healthcare through cutting-edge genomic science.
The reference was built using high-quality DNA sequencing from 53 people of diverse Arab backgrounds in the UAE. The work, conducted in MBRU’s state-of-the-art Center for Applied and Translational Genomics (CATG), uncovered over 110 million base pairs of novel DNA sequences and identified nearly nine million small differences and more than 235,000 larger structural differences specific to Arab populations that have not been reported before. These findings are significant, as global DNA references have historically underrepresented Arab populations — a gap this research helps to close.
The Arab Pangenome Reference supports national and regional precision medicine initiatives by enabling the development of population-specific biomarkers, risk models, and therapeutic targets. One notable discovery was the duplicated gene TAF11L5, found highly enriched in Arab individuals studied but absent from global references. This gene may play a role in regulating other genes and could have implications for understanding disease risk and individual variation in treatment response.
Professor Alawi Alsheikh-Ali, Director General, Dubai Health Authority, and co-author of the study, said: “This achievement strengthens the UAE’s position in genomic science. By building a reference that reflects the genetic diversity of Arab populations, we are enabling more precise and equitable healthcare. It’s a foundational step towards realising the goals of our National Genome Strategy and ensuring that future medical innovations are shaped by data from our own communities.”
Dr. Hanan Al Suwaidi, Acting Provost of MBRU, and co-author of the study said: “The capabilities of the CATG lab were central to the success of this project. From genetic sequencing to advanced bioinformatics, every stage of the research was completed in-house. This level of integration gave us full control over quality and timelines, reflecting Dubai Health’s commitment to building world-class infrastructure and fostering national scientific leaders."
While genomic research has advanced rapidly over the past two decades, much of the foundational data has come from a narrow subset of global populations. This has created blind spots in how genetic risk is understood and addressed across different communities. The Arab Pangenome Reference contributes to a growing international effort to correct this imbalance by introducing high-quality data from a historically underrepresented population.
Dr. Mohammed Uddin, Director of CATG and Associate Professor of Genetics at MBRU, and senior author of the study, said: “This pangenome reference marks a major advancement in our understanding of Arab genomic diversity. It serves as a critical resource for both research discovery and clinical genome diagnostics, with lasting impact for future generations across the region.”
The project also developed ‘PanScan’, a bioinformatics tool to support more complex analysis of human pangenomes. Although not the central focus of the study, PanScan enables researchers to detect gene duplications, novel DNA changes, and complex DNA structures. Now publicly available on GitHub, a common resource used by scientists worldwide, the tool was created to support the Arab Pangenome Reference and similar efforts globally.
Dr. Nasna Nassir, lead author of the study and Assistant Professor at MBRU, said: “To support the Arab Pangenome Reference study, we developed PanScan, a tool designed to identify novel variants, gene duplications, and complex haplotype patterns specific to Arab populations. PanScan was key to uncovering unique genomic insights in our study and is now publicly available to support similar research globally.”
The research reflects Dubai Health’s commitment to advancing learning and discovery through MBRU. The university’s research strategy is focused on contributing to global scientific progress. By investing in foundational genomic research, Dubai Health is helping to ensure that Arab populations are represented in the future of precision healthcare.
The full study is available at:
Dubai Health and GE HealthCare, a leading global medical technology and digital solutions innovator, have signed a Memorandum of Understanding (MoU) to collaborate on enhancing Point-of-Care Ultrasound (POCUS) practices and co-developing innovative AI solutions to support clinical decision-making, ultimately enhancing patient care and outcomes across the UAE and the Middle East and North Africa (MENA) region.
The collaboration combines Dubai Health’s academic and innovation expertise with GE HealthCare’s advanced technological capabilities to enhance medical education, strengthen clinical decision-making, and improve health outcomes throughout the UAE and the broader MENA region.
The MoU will establish Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) as a POCUS Education Center of Excellence and a pioneer in Point-of-Care Ultrasound education across the MENA region.
Key initiatives include: a ‘Train-of-Trainer (TOT)’ structured program to build capacity in certified facilitators and trainers. The Facilitator Training Program will also enhance the scalability and effectiveness of POCUS program delivery and execution across a broader geographical region, enabling wider participation of attendees, students, and delegates.
In addition, the collaboration will extend to the co-development of AI solutions through Dubai Health Innovations, which supports transformative solutions that enhance patient care, drive medical advancements, and improve health outcomes. This partnership will focus on the development and validation of emerging AI technologies in areas of mutual interest, such as radiology and computer vision, aiming to improve diagnostic accuracy, streamline clinical workflows, and facilitate early detection of medical conditions. Through this joint effort, both parties seek to foster innovation, accelerate adoption of cutting-edge AI tools, and contribute to the advancement of healthcare delivery in the region.
Dr. Hanan Al Suwaidi, Acting Chief Academic Officer of Dubai Health and Provost of MBRU said: “This collaboration reflects Dubai Health’s commitment to delivering on our “Patient First” promise through the integration of care, learning, and innovation to elevate healthcare standards. By building capacity in POCUS education and co-developing AI-powered solutions, we are empowering clinicians with next-generation technologies to improve patient outcomes.”
President of GE HealthCare EAGM (Eurasian and African Growth Markets), Konstantinos Deligiannis, said: “This MoU marks a pivotal moment for POCUS advancement in the MENA region. We are excited to partner with Dubai Health to build skills, accelerate knowledge transfer, and strengthen the local and regional healthcare expertise. By combining our advanced ultrasound technology with innovative AI solutions, we are committed to enhancing diagnostic accuracy and efficiency, ultimately contributing to the region’s broader healthcare objectives.”
Dr. Rasha Buhumaid, Vice Dean of Graduate Medical Education, Assistant Professor of Emergency Medicine, and Program Director of POCUS at MBRU, further commented: “This partnership is a significant step toward realizing our vision of positioning MBRU as a Center of Excellence for Point-of-Care Ultrasound education. Through the Facilitator Training Program and other initiatives, this collaboration enables us to strengthen the integration of POCUS into clinical practice, build sustainable expertise, and support better outcomes at the point of care and across the health system.”
Professor Nabil Zary, Senior Director of the Institute of Learning at Dubai Health, also noted: “Education is at the heart of sustainable healthcare transformation. This partnership with GE HealthCare enables us to deliver high-impact, evidence-based training in POCUS that not only equips clinicians with advanced skills but also fosters a culture of continuous learning and innovation.”
The MoU between the two parties will be in effect for two years and is renewable by mutual agreement.
Scientists at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), which leads the Learning and Discovery missions of Dubai Health, have identified a novel genetic disorder affecting children’s growth and development. Published in a leading journal, The American Journal of Human Genetics, this study identifies a problem in the FBXO22 gene, which causes various health issues in children, including growth restriction, intellectual disability, and other physical challenges. This discovery could enable more accurate diagnosis and genetic counseling, supporting informed family planning and long-term care for affected families.
Professor Alawi Alsheikh-Ali, Chief Academic Officer of Dubai Health and Provost of MBRU, said, “At Dubai Health, research is central to how we advance patient care and serve our communities. This study highlights the power of global collaboration and the impact of translational research at MBRU. We are proud to lead this important genetic discovery as part of a global collaboration and generate knowledge that holds real promise for patients and their families.”
The study included an international team of scientists and clinicians, led by Dr. Ahmad Abou Tayoun from MBRU. The team identified that mutations in the FBXO22 gene impair its function, leading to various developmental abnormalities. These include severe pre- and postnatal growth restrictions, intellectual disability, and additional complications affecting the cardiac, gastrointestinal, and skeletal systems.
Dr. Ahmad Abou Tayoun, Associate Professor of Genetics at MBRU and Director of Dubai Health’s Genomic Medicine Center, said, “This study demonstrates how genetic research on local populations can uncover the root causes of complex pediatric conditions, provide a framework for more accurate diagnosis and counseling, and contribute to global efforts to better understand the human genome. Through this discovery, we can provide a framework for more accurate diagnosis and genetic counseling, offering affected families meaningful answers to support future family planning. This work also highlights the importance of close collaborations with clinical teams, particularly the endocrinology team led by Dr. Nandu Thalange, who first identified and investigated the index case.”
The study included 16 cases from 14 families across the UAE, Saudi Arabia, Oman, and Lebanon. The team used advanced short- and long-read sequencing technology to study the children’s DNA and find the FBXO22 problem. The condition showed overlapping features with other known genetic disorders, further highlighting the critical role of FBXO22 in normal growth and development.
Dr. Fahad Ali, Assistant Professor of Molecular Biology at MBRU, said, “A key aspect of this study was identifying a unique marker in the blood that serves as a molecular fingerprint for this condition. This discovery could pave the way for a simple diagnostic test, enabling earlier detection and better support for affected families.”
The study was supported by funding from the Al Jalila Foundation, MBRU, and the King Abdullah University of Science and Technology (KAUST) Center of Excellence for Smart Health, among others. It reflects MBRU’s ongoing mission to address pressing health challenges through innovative research and global partnerships.
Creation of a comprehensive genetic representation for more than 2.5 billion people across the Middle East and South Asia could make a major contribution towards advancing precision medicine, a publication in Nature Medicine reveals.
Traditional genetic research has mainly relied on linear reference genomes, which is like having a single, standard version of human DNA that scientists compare everyone's genetic information against. This works well for studying individual genetics but does not capture all the complexities and differences found in diverse populations.
The Arab Pangenome Reference (APR) takes a different approach. Instead of relying on just one "standard" genome, it includes a collection of many different genetic versions specific to the Arab population. This helps scientists see the full picture of genetic diversity, including variations and unique traits that might be missed using the old method.
The international group of researchers led by the Center for Applied and Translational Genomics (CATG) at Mohammed Bin Rashid University of Medicine and Health Sciences, in partnership with the University of Birmingham, Dubai published their findings today (4 Mar) in Nature Medicine. Authors included Nasna Nassir, Mohamed A. Almarri, Hosneara Akter, Hamda Hassan Khansaheb, K. M. Furkan Uddin, Ahmad Abou Tayoun, Stefan Du Plessis, Marc Haber, Alawi Alsheikh-Ali and Mohammed Uddin. Nature Medicine is recognized for its rigorous peer-review process and its commitment to disseminating high-quality studies and opinion pieces that advance our understanding of human health.
Professor Alawi Alsheikh-Ali, Deputy CEO and Chief Academic Officer of Dubai Health and Provost of Mohammed Bin Rashid University of Medicine and Health Sciences, commented: “This publication provides a comprehensive and inclusive perspective on human genetic diversity, ensuring that the unique genetic landscapes of the Middle East and South Asia are represented. Integration of these pangenomes into global genomic databases will unlock new discoveries and represents a vital step in advancing health for humanity.”
Professor Yusra Mouzughi, Provost University of Birmingham Dubai commented: “At the University of Birmingham, we pride ourselves on ‘research that changes lives’. This latest research demonstrates the impact of our strong partnership between University of Birmingham Dubai and Dubai Health to deliver research that fundamentally advances science and discovery, creating a new understanding of genetic diversity amongst Arabs and enabling a deeper understanding of the genetic origins of disease.”
Dr. Mohammed Uddin Director of the Center for Applied and Translational Genomics (CATG) at Mohammed Bin Rashid University of Medicine and Health Sciences, commented: “The APR is the first reference genome constructed to capture the genetic diversity among Arabs. This landmark resource aims to enhance early diagnosis and personalized treatments for genetic diseases that are prevalent in the region. This research uncovered millions of base pairs of novel human DNA sequences, which will contribute to a deeper understanding of the genetic origins of diseases and traits. Our goal is to construct graph pangenomes encompassing the entire Middle East and South Asia, aiming to accelerate the adoption of precision medicine in these regions.”
Co-author Marc Haber, from the University of Birmingham Dubai, commented: “The precision offered by pangenomic approaches is particularly beneficial for studying rare and previously undetected disease-causing variants which paves the way for better understanding and treatment of these conditions, leading to new discoveries in population genetics, disease susceptibility and drug response.”
Professor Stefan Du Plessis, Dean of Research and Graduate Studies at MBRU commented: “At Dubai Health, our Discovery Mission embodies our commitment to innovation, research, and the advancement of healthcare. This publication emphasises the importance of collaborative research in making advanced genomic references a routine part of diagnostics and healthcare. As we move forward, this comprehensive genetic approach promises to reshape our understanding of health and disease, ultimately improving healthcare for millions.”